A qualified computer engineering graduate, Akshay Kedari holds a commensurate passion for both writing and programming. Presently, Akshay develops content for healthcareopportunity.org and similar other portals. Apart from penning down pieces related to digitized healthcare, pharmaceuticals, and more, Akshay spends his free time enjoying bike rides and good food. He can be contacted at- [email protected] | https://twitter.com/axeyked
CureVac’s vaccine platform has the potential to improve CEPI’s ability to respond to the emerging Disease X, claims CEPI CEO. In a move to defeat the next pandemic, the …
Lynparza was the first PARP drug to reach the market after it was approved for ovarian cancer in U.S. Leading multinational pharmaceutical and biopharmaceutical firm, AstraZeneca Plc., has recently …
Eyenovia, Inc., has reportedly declared attaining positive results from its second MicroStat Phase III study, known as MIST-2. If reports are to be believed this study evaluated the efficacy …
The drug has been specifically developed for the nonalcoholic fatty liver disease (NASH) The clinical trial is expected to report by the third quarter of 2019 Boehringer Ingelheim (Boehringer), …
Agios Pharmaceuticals, Inc. has recently announced that the FDA has accepted the supplemental New Drug Application (sNDA) of the company for TIBSOVO®. Apparently, the drug would be used in …
The Swiss biopharmaceutical company, CRISPR Therapeutics, and Durham-based leading developer of new AAV (adeno-associated viral)-based gene therapies, StrideBio Inc., have recently announced the extension of their development & option …
Roche is working closely with FDA to make this potential new personalized medicine available as soon as possible. Roche, the Swiss multinational healthcare company, has been recently reported to …
The new software capabilities have been added with the intention of further advancing the development of medical devices It aims enable connected healthcare solutions to scale themselves up significantly, …
The study found that about 90% of patients receiving the drug combination therapy turned out to be alive after 12 months. Merck & Co. Inc. and Pfizer Inc. are …
Summit Therapeutics, a clinical-stage drug development company based in the UK, has reportedly proclaimed that its first patient has been dosed in the global Phase 3 clinical trials of …
